ASCO/EHA/ICML 2023 – Alessandra Tedeschi

Alessandra Tedeschi gives insights into the health-related quality of life data from the ASPEN study conducted in patients with Waldenström macroglobulinemia, discusses the notable results from the extended follow-up of the SEQUOIA study in patients with treatment-naïve chronic lymphocytic leukemia as well as the clinical activity of zanubrutinib in the setting of R/R marginal zone lymphoma while finally depicting her personal highlights from this year’s EHA congress.

Here is the full ASCO/EHA/ICML 2023 report.

More posts